Search clinical trials for: Placebo of MCI-186

Total 31149 results

Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
Mitsubishi Tanabe Pharma Corporation

Terminated

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Acute Ischemic Stroke

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Mitsubishi Tanabe Pharma Corporation

Completed

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Type 2 Diabetes
Mitsubishi Tanabe Pharma Corporation

Terminated

A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

France, Poland, Spain, Serbia, South Africa, Czech Republic, Germany, Macedonia, The Former Yugoslav Republic of, Italy, United Kingdom
Cerebos Pacific Limited

Unknown

CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women

Cognitive Change

Taiwan
Mitsubishi Tanabe Pharma Corporation

Completed

Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

Dyslipidemia | Chronic Kidney Disease | Hyperphosphatemia | Dialysis

Poland, Ukraine, Serbia, Russian Federation, Hungary, Malaysia, Italy, Macedonia, The Former Yugoslav Republic of
Mitsubishi Tanabe Pharma Corporation

Completed

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Puerto Rico
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke

Acute Ischemic Stroke (AIS)

Netherlands, Finland, United Kingdom
Molecular NeuroImaging
Life Molecular Imaging SA

Completed

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Alzheimer's Disease (AD) | Progressive Supranuclear Palsy (PSP) | Frontal Temporal Dementia (FTD) | Cortical Basal Syndrome (CBS)

United States
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

Chronic Kidney Disease

Belarus, Bulgaria, Romania, Malaysia, Singapore, Thailand, Italy, Lithuania, Latvia, Croatia, Denmark, Israel, Indonesia
Institute for Neurodegenerative Disorders

Terminated

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer's Disease

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia | Dialysis

United States, Canada
First Affiliated Hospital of Fujian Medical University

Completed

Study of 18F-Thretide PET/CT in Patients With Prostate Cancer

Prostate Cancer

China
Invicro

Completed

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

Alzheimer Disease | Healthy Volunteers | Progressive Supranuclear Palsy

United States
Genentech, Inc.

Completed

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Alzheimer's Disease

United States
Molecular NeuroImaging

Completed

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

Alzheimer Disease | Healthy Volunteers | Progressive Supranuclear Palsy

United States
Organon and Co

Completed

A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)

Asthma
Eli Lilly and Company

Completed

A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of the Effects of LY3372689 on the Brain in Healthy Participants

Healthy

United States
Siemens Molecular Imaging

Completed

An Exploratory, Open Label, Single Center Study of [F-18]HX4 (HX4)

Head and Neck Cancer

United States
Invicro

Completed

Assessment of [18F]MNI-1054 as a Marker for LSD1

Healthy Volunteers (HV)

United States
Invicro

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects

Healthy Volunteers

United States
Molecular NeuroImaging

Completed

Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

Alzheimer Disease | Healthy Volunteers | Progressive Supranuclear Palsy

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 (MNI-558)

Alzheimer Disease

United States
Invicro

Completed

Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss

Parkinson Disease | Alzheimer Disease | Healthy Volunteers

United States
Invicro

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-1054

Healthy Volunteers

United States
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment

Healthy | Hepatic Impairment

Japan
Mitsubishi Tanabe Pharma America

Completed

Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment

Healthy | Renal Impairment

Japan
Alzheimer's Disease Expert Lab (ADEL), Inc.
Oscotec Inc.

Recruiting

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-LY3950321-01 Biodistribution and Safety Study

Radiation Exposure | Diagnostic Agent Adverse Reaction

United States
Chang Gung Memorial Hospital

Recruiting

Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy

Progressive Supranuclear Palsy

Taiwan
CHDI Foundation, Inc.

Completed

Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers (LONGPDE10)

Huntington's Disease

Sweden, Denmark, Netherlands, Norway
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Assistance Publique Hopitaux De Marseille

Recruiting

Aging Stereotypes and Prodromal Alzheimer's Disease (AGING)

Mild Cognitive Impairment (MCI)

France
Invicro

Completed

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

Alzheimer Disease | Healthy Volunteers

United States
Molecular NeuroImaging

Completed

Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects

Healthy Volunteers

United States
AstraZeneca

Completed

A Study to Compare the Pharmacokinetics of Budesonide Delivered by PT027 Compared With Pulmicort Flexhaler (ELBRUS)

Relative Bioavailability

United States
Kineta Inc.

Completed

A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis

Plaque Psoriasis

Canada
Mitsubishi Tanabe Pharma Corporation

Completed

A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

Chronic Kidney Disease | Hyperphosphatemia

France, Poland, United Kingdom, Spain, South Africa, Australia, Czech Republic, Germany, Hungary, Italy, Austria
Guang'anmen Hospital of China Academy of Chinese...
Beijing Anzhen Hospital

Completed

Study of Herbal Formula Corresponding to Syndrome in Treating Post Percutaneous Coronary Intervention (PCI) Patients With Coronary Heart Disease (CHD)

Coronary Heart Disease

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer

Metastatic Prostate Cancer

United States
Shanghai Zerun Biotechnology Co.,Ltd
Guangxi Center for Disease Control and Prevention

Completed

A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.

Cervical Intraepithelial Neoplasia | Human Papilloma Virus Infection Type 16 | Human Papilloma Virus Infection Type 18
Peking Union Medical College Hospital

Recruiting

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Kineta Inc.

Completed

Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers

Healthy

United States
Invicro

Completed

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Healthy Male Volunteers

United States

Search clinical trials for: Placebo of MCI-186

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations